Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden death in adolescents and initial detection is often difficult. A new UCSF study finds that Artificial Intelligence-enhanced ...

Updates to national guidelines for the management of hypertrophic cardiomyopathy (HCM) endorse cardiac myosin inhibitor use in certain cases, greenlight more intensive physical activity, and expand ...

Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden death in adolescents and initial detection is often difficult. A new UC San Francisco study finds that Artificial Intelligence-enhanced ...

The American College of Cardiology (ACC) and the American Heart Association (AHA) today released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten’s label has been updated to include data from VALOR-HCM. Mavacamten is linked to less need for septal ...

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

The emergence of novel pharmacotherapies, minimally-invasive procedures and gene-directed approaches shall fundamentally alter the Hypertrophic Cardiomyopathy therapeutic landscape. Amongst all ...

Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today ...

The FDA has approved the drug Camzyos to treat obstructive hypertrophic cardiomyopathy (HCM). A second drug is currently under review. Other medications and lifestyle strategies can also help manage ...

Cytokinetics, Incorporated announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for aficamten, a cardiac myosin inhibitor aimed at treating ...